Global EditionASIA 中文雙語Fran?ais
    Business
    Home / Business / Companies

    BeiGene protects the world with affordable Chinese therapies

    By Liu Zhihua | China Daily | Updated: 2019-12-30 10:38
    Share
    Share - WeChat
    Wu Xiaobin, president of BeiGene. [Photo provided to China Daily]

    The two drugs were approved only six months later as two foreign anti-PD-1 treatments entered the China market, and followed shortly by a third domestic PD-1 treatment early this year.

    BeiGene's anti-PD-1 treatment also obtained approval from the Chinese drug regulatory authorities on Saturday.

    The company has been also implementing about 20 clinical trial programs globally on Brukinsa's efficacy on other types of blood or lymph tumors, with high hope to get more market approvals in the near future.

    The company, which has nearly 10 new drug candidates in pipeline, is a partner in a global strategic oncology collaboration with Amgen, a California-based biopharmaceutical company that is a global leader in this niche.

    Chinese biotech firms are increasingly offering China-developed high-quality treatments to Chinese patients, which will help challenge the expensive prices of imported drugs, Wu said.

    With innovative drugs such as anti-PD-1 and Brukinsa, Chinese drug companies also have the ability to offer treatment options for patients abroad, especially those in the Belt and Road economies, he said.

    Wu joined the Beijing-headquartered company in 2018 from Pfizer China, which he headed since 2009.

    His jump to the Chinese biotech startup founded in 2010 surprised many as he had more than 26 years of rich experience in the pharmaceutical industry, including 17 years leading China operations of big-name multinational pharmaceuticals such as Wyeth and Bayer.

    He returned to Beijing in 1996 to co-build Bayer's China branch as marketing head. Prior, he was in Germany where he received a master's degree in molecular biology and a PhD in biochemistry and pharmacology from the University of Konstanz. He started his career at Bayer's sales and marketing in 1992.

    In 2004, he rose to general manager of Wyeth China. In 2009, as Pfizer acquired Wyeth, he was named head of the combined group.

    He also served as vice chairman of the R&D-based Pharmaceutical Association Committee of the China Association of Enterprises with Foreign Investment since 2008.

    Under his belt are numerous industry awards, including the "Person of the Year" in Healthy China Awards 2017, "2017 Top 10 Most Influential Persons in the Chinese Healthcare Industry" and the "2017 Social Responsibility Eminent Person Award".

    |<< Previous 1 2   
    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    精品无码日韩一区二区三区不卡| 久久久无码一区二区三区| 日韩午夜福利无码专区a| 人看的www视频中文字幕| 亚洲综合av永久无码精品一区二区| 国产 日韩 中文字幕 制服| 亚洲熟妇无码八AV在线播放| 亚洲人成影院在线无码观看 | 亚洲欧美日韩中文久久| 亚洲AV无码一区东京热| 国产精品99久久久精品无码| 精品久久久久久中文字幕大豆网| 未满小14洗澡无码视频网站| 东京热人妻无码一区二区av | 人妻丝袜中文无码av影音先锋专区| 日韩精品无码AV成人观看| 中文字幕精品视频| 久久精品aⅴ无码中文字字幕不卡 久久精品aⅴ无码中文字字幕重口 | 久久久精品人妻无码专区不卡| 无码人妻熟妇AV又粗又大| 精品亚洲AV无码一区二区三区| 狠狠躁天天躁无码中文字幕 | 狠狠躁狠狠爱免费视频无码| 亚洲av无码成h人动漫无遮挡 | 精品人妻中文字幕有码在线| 中文无码vs无码人妻| 久久久久无码国产精品不卡| 国产AV无码专区亚洲AV男同| 亚洲av无码潮喷在线观看| 无码人妻一区二区三区免费看| 亚洲精品午夜无码电影网| 亚洲日产无码中文字幕| 三上悠亚ssⅰn939无码播放| 最近中文字幕大全2019| 亚洲中文字幕视频国产| 日韩欧美中文字幕一字不卡| 精品久久久久久久中文字幕| 日本乱偷人妻中文字幕在线| 亚洲伊人久久综合中文成人网 | 中文字幕无码播放免费| 国产资源网中文最新版|